Rheumatoid arthritis

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting

Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Yoshino Inoue, Yoshihisa Fujino, Yoshiya Tanaka

10.1136/annrheumdis-2020-219699

April 7, 2021

Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial

Ho So, Isaac T Cheng, Sze-Lok Lau, Evelyn Chow, Tommy Lam, Vivian W Hung, Edmund K Li, James F Griffith, Vivian W Lee, Lin Shi, Junbin Huang, Kitty Yan Kwok, Cheuk-Wan Yim, Tena K Li, Vincent Lo, Jolie Lee, Jack Jock-Wai Lee, Ling Qin, Lai-Shan Tam

10.1136/annrheumdis-2021-219846

April 2, 2021

Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial

Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Delphine Bertrand, Patrick Verschueren

10.1136/annrheumdis-2020-219825

April 2, 2021

Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020

Wenhui Xie, Hong Huang, Guangtao Li, Yanjie Hao, Yanni Gui, Yu Wang, Xuerong Deng, Juan Zhao, Yan Geng, LanLan Ji, Xiaohui Zhang, Zhibo Song, Zhuoli Zhang

10.1136/annrheumdis-2021-220112

April 2, 2021

Circulating blood metabolite trajectories and risk of rheumatoid arthritis among military personnel in the Department of Defense Biorepository

Karen H Costenbader, Michael DiIorio, Su H Chu, Jing Cui, Jeffrey A Sparks, Bing Lu, LauraKay Moss, Lindsay Kelmenson, Marie Feser, Jess Edison, Clary Clish, Jessica Lasky-Su, Kevin D Deane, Elizabeth W Karlson

10.1136/annrheumdis-2020-219682

March 22, 2021

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng, Julie A Di Paolo

10.1136/annrheumdis-2020-219012

March 19, 2021

TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors

Cecilia Ansalone, John Cole, Sabarinadh Chilaka, Flavia Sunzini, Shatakshi Sood, Jamie Robertson, Stefan Siebert, Iain B McInnes, Carl S Goodyear

10.1136/annrheumdis-2020-219262

March 10, 2021

Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study

Hieronymus TW Smeele, Esther Röder, Hetty M Wintjes, Laura JC Kranenburg-van Koppen, Johanna MW Hazes, Radboud JEM Dolhain

10.1136/annrheumdis-2020-219547

February 10, 2021

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J Abraham Simon, Herbert S B Baraf, Uma Kumar, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Guo, Chantal Tasset, John S Sundy, Angelika Jahreis, Mark C Genovese, Neelufar Mozaffarian, Robert B M Landewé, Sang-Cheol Bae, Edward C Keystone, Peter Nash

10.1136/annrheumdis-2020-219214

January 27, 2021

Novel autoantibodies identified in ACPA-negative rheumatoid arthritis

Ketian Li, Wenxiu Mo, Lijun Wu, Xunyao Wu, Cainan Luo, Xinyue Xiao, Xinmiao Jia, Huaxia Yang, Yunyun Fei, Hua Chen, Fengchun Zhang, Yongzhe Li, Lidan Zhao, Xuan Zhang

10.1136/annrheumdis-2020-218460

January 15, 2021